


RS-127445 hydrochloride

Cat. No.:	HY-15419
CAS No.:	199864-86-3
Molecular Formula:	C ₁₇ H ₁₇ ClFN ₃
Molecular Weight:	317.79
Target:	5-HT Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 31 mg/mL (97.55 mM)
 H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.1467 mL	15.7337 mL	31.4673 mL
	5 mM	0.6293 mL	3.1467 mL	6.2935 mL
	10 mM	0.3147 mL	1.5734 mL	3.1467 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (7.87 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.87 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.87 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

RS-127445 hydrochloride is a selective, high affinity, orally bioavailable 5-HT_{2B} receptor antagonist with a pK_i of 9.5. RS-127445 hydrochloride shows 1000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites^[1].

IC₅₀ & Target

sPLA2 5.5 (pKi)	5-HT ₃ Receptor <6 (pKi)	5-HT ₅ Receptor <6 (pKi)	5-HT ₆ Receptor <6 (pKi)
--------------------	--	--	--

	5-HT _{2A} Receptor 6.3 (pKi)	5-HT _{2C} Receptor 6.4 (pKi)	5-HT _{2B} Receptor 9.5 (pKi)
In Vitro	<p>RS-127445 is found to have nanomolar affinity for the 5-HT_{2B} receptor (pK_i=9.5±0.1) and 1,000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites. RS-127445 potently displaces [³H]-5-HT from human recombinant 5-HT_{2B} receptors expressed in CHO-K1 cells. The affinity (pK_i value) of RS-127445 for the 5-HT_{2B} receptor is 9.5±0.1 (n=9). RS-127445 is selective for the 5-HT_{2B} receptor, having approximately 1000 fold lower affinity for the human recombinant 5-HT_{2A}, 5-HT_{2C}, 5-HT₅, 5-HT₆ and 5-HT₇ receptors, a 5-HT_{1A} receptor in rat brain membranes, a 5-HT_{1B/D} receptor in bovine caudate, and a monoamine uptake site in rabbit platelets. RS-127445 potently blocks the 5-HT (10 nM) evoked increases in intracellular calcium concentrations in the HEK-293 cells expressing the 5-HT_{2B} receptor (pIC₅₀ of 10.4±0.1). In cells expressing human recombinant 5-HT_{2B} receptors, RS-127445 potently antagonizes 5-HT-evoked formation of inositol phosphates (pK_B=9.5±0.1) and 5-HT-evoked increases in intracellular calcium (pIC₁₀=10.4±0.1). RS-127445 also blocks 5-HT-evoked contraction of rat isolated stomach fundus (pA_{2B}=9.5±1.1) and (±)α-methyl-5-HT-mediated relaxation of the rat jugular vein (pA₂=9.9±0.3)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>		
In Vivo	<p>In rats, the fraction of RS-127445 that is bioavailable via the oral or intraperitoneal routes is 14 and 60% respectively. Intraperitoneal administration of RS-127445 (5 mg/kg) produced plasma concentrations predicted to fully saturate accessible 5-HT_{2B} receptors for at least 4 h. RS-127445 (5 mg/kg) is administered to rats by oral, intraperitoneal and intravenous routes. Peak plasma concentrations are rapidly achieved with the highest concentrations being found at the first time-point measured following intravenous and intraperitoneal administration (0.08 h) and by 0.25 h following dosing by the oral route of administration. RS-127445 is cleared from plasma with an estimated terminal elimination half-life of approximately 1.7 h. The bioavailability of RS-127445, when administered by the oral and intraperitoneal routes is approximately 14 and 62% of that obtained by intravenous administration. Approximately 60% of an intraperitoneal dose and 14% of the oral dose of RS-127445 (5 mg/kg) is bioavailable^[1]. RS-127445 (1-30 mg/kg), dose-dependently reduces faecal output, reaching significance at 10 and 30 mg/kg (n=6-11). In blood and brain, >98% of RS-127445 is protein-bound^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>		

PROTOCOL

Cell Assay ^[1]	<p>HEK-293 cells expressing the human 5-HT_{2B} receptor are incubated with [³H]-myoinositol (1.67 µCi/mL) in 162 cm² flasks overnight at 37°C in an inositol free Ham's F12 medium containing 10% dialyzed foetal bovine serum. The cells are harvested, washed five times with phosphate buffered saline and resuspended in inositol free Ham's F12 media at density of approximately 3×10⁶ cells/mL. RS-127445 (10 µM) is initially dissolved in 10% (v/v) DMSO with 90% inositol free Ham's F12 medium. Subsequent dilutions are made with inositol free Ham's F12 medium. 5-HT is dissolved in inositol free Ham's F12 medium containing 100 mM LiCl and 1 mM ascorbate. RS-127445, vehicle or other antagonists are pre-incubated with 240 µL of cell suspension at 37°C for 20 min. The reactions are initiated by addition of 5-HT. Sixty minutes later, the reactions are terminated by adding 50 µL of ice-cold 20% perchloric acid, chilled in an ice-water bath for 10 min and then neutralized with 160 µL of 1 N KOH. Each sample is diluted with 2 ml of 50 mM Tris-HCl, pH 7.4 at room temperature. The aqueous portion (2.2 mL) is transferred onto Dowex AG1X8 columns (1 ml, 1 : 1, w/v) which had been washed with 5 ml of distilled water. The columns are then washed with 18 ml of distilled water and the inositol phosphates are eluted with 3 ml of 1 N HCl. The eluted radioactivity is determined by liquid scintillation spectroscopy using a Packard 1900CA analyzer^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
Animal Administration ^{[1][2]}	<p>Rats^[1]</p> <p>Male Sprague-Dawley rats (200 g) are used. To compare the plasma kinetics of RS-127445 following different routes of administration, 90 rats are distributed into three treatment groups of 30 rats each. A single dose of RS-127445 (5 mg/kg) dissolved (2.5 mg/mL) in ethanol:propylene glycol : water (10 : 50 : 40, v:v:v), is administered to each rat. At 0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h after dosing, the rats are anaesthetized and blood samples are collected by cardiac puncture.</p> <p>Mice^[2]</p> <p>Adult male C57BL/6J mice (25-30 g) are used. The effects of RS-127445 (1 nM-10 µM, single concentration per tissue, 15 min contact time) or vehicle (5 or 50 µL DMSO) are expressed as the percentage change in amplitude compared with the mean</p>

amplitude of four pre-drug, post-EFS contractile responses. The results are analysed using a two-sample equal variance t-test.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Mol Neurobiol. 2023 Sep 25.
- Authorea. September 19, 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bonhaus DW, et al. RS-127445: a selective, high affinity, orally bioavailable 5-HT_{2B} receptor antagonist. Br J Pharmacol. 1999 Jul;127(5):1075-82.

[2]. Bassil AK, et al. Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT_{2B} receptor in rodent large bowel physiology. Br J Pharmacol. 2009 Sep;158(1):252-8

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA